



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)

PRODUCT INFORMATION



Orforglipron

Item No. 39741

CAS Registry No.: 2212020-52-3
Formal Name: 3-[[[1S,2S)-1-[2-[[[4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[[4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcyclopropyl]-1,2,4-oxadiazol-5(2H)-one

Synonyms: LY3502970, OWL833

MF: C₄₈H₄₈F₂N₁₀O₅


FW: 883.0

Purity: ≥95%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Orforglipron is supplied as a solid. A stock solution may be made by dissolving the orforglipron in the solvent of choice, which should be purged with an inert gas. Orforglipron is soluble in the organic solvent methanol.

Description

Orforglipron is a nonpeptide agonist of the glucagon-like peptide 1 receptor (GLP-1R).¹ It induces cAMP accumulation in HEK293 cells expressing human GLP-1R (EC₅₀ = 3.05 nM) and is selective for GLP-1R over the glucagon receptor (GCGR), gastric inhibitory polypeptide (GIP) receptor, and GLP-2R at 100 nM. Orforglipron (0.1, 1, or 10 mg/kg) prevents increases in blood glucose levels in glucose-injected fasted mice expressing human GLP-1R but not in glucose-injected *Glp1r*^{-/-} fasted mice. *In vivo*, orforglipron (5.4 mg/kg) decreases blood glucose and serum insulin levels in glucose-injected cynomolgus monkeys. It reduces mean food intake in cynomolgus monkeys when administered at doses of 0.05 or 0.1 mg/kg per day.

Reference

1. Kawai, T., Sun, B., Yoshino, H., *et al.* Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. *Proc. Natl. Acad. Sci. USA* **117**(47), 29959-29967 (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/24/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM